<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692614</url>
  </required_header>
  <id_info>
    <org_study_id>0140-001</org_study_id>
    <secondary_id>MK0140-001</secondary_id>
    <secondary_id>2008_521</secondary_id>
    <nct_id>NCT00692614</nct_id>
  </id_info>
  <brief_title>A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)</brief_title>
  <official_title>A Phase IIb, Randomized, Masked, Sham-Controlled, Clinical Trial to Study the Efficacy and Safety of the Helical Triamcinolone Acetonide Implant (MK0140) in Diabetic Patients With Clinically Significant Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the treatment effect of three doses of the I-vation TA implant&#xD;
      (MK0140) in diabetic patients with clinically significant macular edema.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in OCT retinal thickness; evaluate the safety and tolerability of doses.</measure>
    <time_frame>After 12 months of therapy.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of visual acuity; change from baseline in OCT center-point retinal thickness; the need for focal/grid laser photocoagulation during the study; the progression of diabetic retinopathy</measure>
    <time_frame>After 12 months of therapy.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mcg triamcinolone acetonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mcg triamcinolone acetonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>925 mcg triamcinolone acetonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>sham control - not implanted, no medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone acetonide</intervention_name>
    <description>100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>MK0140</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has clinically significant macular edema as a result of their diabetes (Type I&#xD;
             or Type 2)&#xD;
&#xD;
          -  Patient has in the study eye, 20/40 - 20/160 vision&#xD;
&#xD;
          -  Patient has Type 1 or Type 2 diabetes&#xD;
&#xD;
          -  Patient agrees to remain abstinent or use (or have their partner use) 2 acceptable&#xD;
             methods of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has had any active ocular infection in either eye&#xD;
&#xD;
          -  Patient has intraocular pressure &gt; 22 mmHg or a diagnosis of glaucoma&#xD;
&#xD;
          -  Patient has cystoid macular edema in the study eye&#xD;
&#xD;
          -  Patient has a history of elevated IOP in response to ocular steroid therapy in either&#xD;
             eye&#xD;
&#xD;
          -  Patient has had intraocular surgery in the study eye within 6 months prior to Visit 1&#xD;
&#xD;
          -  Patient has an HbAIc value &gt; 10% at Visit 1&#xD;
&#xD;
          -  Patient has within the last 4 months initiated intensive insulin treatment or plan to&#xD;
             do so in the next 4 months&#xD;
&#xD;
          -  Patient has a history of cancer within 5 years prior to signing informed consent&#xD;
&#xD;
          -  Patient has clinically-relevant chronic renal failure&#xD;
&#xD;
          -  Patient has high blood pressure&#xD;
&#xD;
          -  Patient has coronary heart disease&#xD;
&#xD;
          -  Patient has known allergies to steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

